1046OPreliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. (23rd October 2018) - Ho, A L; Chau, N; Bauman, J; Bible, K; Chintakuntlawar, A; Cabanillas, M E; Wong, D J; Braña Garcia, I; Brose, M S; Boni, V; Even, C; Razaq, M; et al.